JERUSALEM, Oct. 31,
2024 /PRNewswire/ -- Scinai
Immunotherapeutics Ltd. (Nasdaq: SCNI), a
biopharmaceutical company specializing in inflammation and
immunology (I&I) biological products and providing CDMO
services through its Scinai Bioservices unit, today announced that
it will be showcasing its innovative I&I product pipeline in
partnership meetings and exhibiting its CDMO services at the
BIO-Europe 2024 conference, taking place November 4-6 in Stockholm, Sweden.
Scinai's CEO, Mr. Amir Reichman,
and CTO, Dr. Dalit Weinstein-Fischer
will be holding meetings during the conference days with:
- Prospective clients of the company's end-to-end biologics
CDMO services.
- Potential pharma partners in the field of I&I interested in
co-developing or in-licensing one of Scinai's innovative
NanoAbs.
- Potential pharma partners in the field of dermatology
interested in Scinai's drug development program for local treatment
of mild to moderate plaque psoriasis – "the Botox-like solution for
psoriatic patients"
- Institutional and private investors interested in SCNI's value
proposition.
Additional interested parties are encouraged to schedule a
meeting through the conference partnering platform or to email
Scinai at bd@scinai.com to schedule a meeting. Throughout the
conference, Scinai will also be available at exhibitor booth
#150 to showcase its CDMO services.
About Scinai Immunotherapeutics
Scinai
Immunotherapeutics Ltd. (Nasdaq: SCNI) is a biopharmaceutical
company with two complementary business units, one focused on
in-house development of inflammation and immunology (I&I)
biological therapeutic products beginning with an innovative,
de-risked pipeline of nanosized VHH antibodies (NanoAbs) targeting
diseases with large unmet medical needs, and the other a boutique
CDMO providing biological drug development, analytical methods
development, clinical GMP manufacturing, and pre-clinical and
clinical trial design and execution services to early stage biotech
companies. Company website: www.scinai.com.
Company Contacts
Investor Relations | +972 8 930 2529
| ir@scinai.com
CDMO and Partnering | +972 8 930 2529 | bd@scinai.com
Forward-Looking Statements
This press release
contains forward-looking statements within the meaning of the
Private Litigation Reform Act of 1995. Words such as "expect,"
"believe," "intend," "plan," "continue," "may," "will,"
"anticipate," and similar expressions are intended to identify
forward-looking statements. All statements, other than statements
of historical facts, are forward-looking statements. These
forward-looking statements reflect management's current views with
respect to certain current and future events and are subject to
various risks, uncertainties and assumptions that could cause the
results to differ materially from those expected by the management
of Scinai Immunotherapeutics Ltd. Risks and uncertainties include,
but are not limited to; the risk that the Scinai will not be able
to sign agreements with other potential clients of the CDMO
business; lower than anticipated revenues of Scinai's CDMO business
in 2024 and thereafter; a delay in the commencement and results of
pre-clinical and clinical studies; the risk of delay in, Scinai's
inability to conduct, or the unsuccessful results of, its research
and development activities, including the contemplated in-vivo
studies and a clinical trial; the risk that Scinai will not be
successful in expanding its CDMO business or in-license other
NanoAbs; the risk that Scinai may not be able to secure additional
capital on attractive terms, if at all; the risk that the
therapeutic and commercial potential of NanoAbs will not be met or
that Scinai will not be successful in bringing the NanoAbs towards
commercialization; the risk of a delay in the preclinical and
clinical trials data for NanoAbs, if any; the risk that Scinai's
business strategy may not be successful; Scinai's ability to
acquire rights to additional product opportunities; Scinai's
ability to enter into collaborations on terms acceptable to Scinai
or at all; timing of receipt of regulatory approval of Scinai's
manufacturing facility in Jerusalem, if at all or when required; the
risk that the manufacturing facility will not be able to be used
for a wide variety of applications and other treatment
technologies; the risk that drug development involves a lengthy and
expensive process with uncertain outcomes; and the risk that the
Company will otherwise be unable to remain compliant with the
continued listing requirements of Nasdaq;. More detailed
information about the risks and uncertainties affecting the Company
is contained under the heading "Risk Factors" in the Company's
Annual Report on Form 20-F filed with the Securities and Exchange
Commission ("SEC") on May 15, 2024,
and the Company's subsequent filings with the SEC. Scinai
undertakes no obligation to revise or update any forward-looking
statement for any reason.
Logo:
https://mma.prnewswire.com/media/2310190/Scinai_Immunotherapeutics_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/scinai-leadership-to-showcase-companys-cgmp-biologics-cdmo-and-innovative-ii-pipeline-during-bio-europe-2024-302292791.html
SOURCE Scinai Immunotherapeutics Ltd.